ZYXI Earnings Prediction
The chart below shows how ZYXI performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ZYXI sees a +0.26% change in stock price 10 days leading up to the earnings, and a -5.29% change 10 days following the report. On the earnings day itself, the stock moves by +1.92%. This data can give you a slight idea of what to expect for the next quarter's release.
ZYXI Key Earning Data
ZYXI Earnings Analysis
Positive
Successful Revenue Growth: 2024 was a successful year for Zynex as we continue to grow revenue and drive profitability.
Revenue Stream Diversification: We have made strides in diversifying our revenue streams with the addition of several new products, including bracing, cold and compression products.
Revenue and Order Growth: Revenue increased 4% in 2024 and order growth was 16% in the year.
Sales Rep Efficiency Increase: The total number of sales reps decreased, but revenue per rep increased 22% to $490,000 on average in 2024.
Positive Test Results: We received positive test results on our NiCO pulse oximeter in multiple trials at Duke University and the University of California in San Francisco.
Enhanced Patient Outcomes: The NiCO pulse oximeter technology is expected to significantly improve patient outcomes, especially for individuals with darker skin pigmentation.
FDA Submission Timeline: We anticipate FDA submission for the NiCO pulse oximeter in the next 30 to 60 days, with potential clearance by Q4 2025.
Cash Balance Increase: Our cash balance increased to $39.6 million, up 5% from Q3's balance of $37.6 million, indicating strong financial health.
Consistent Revenue Growth: We have consistently demonstrated growth over the past several years, with revenues now nearly 20 times higher than a decade ago.
Negative
Payment Suspension Impact: Tricare temporarily suspended payments, creating uncertainty in revenue projections for 2025.
Tricare Revenue Impact: Tricare represents 20% to 25% of revenue, indicating a significant potential revenue loss if the suspension is upheld.
Workforce Reduction Impact: The company has reduced its workforce by 15%, which may indicate underlying operational challenges.
Profitability Decline Analysis: Net loss of $615,000 in Q4 2024 compared to a net income of $1.2 million in Q4 2023, showing a decline in profitability.
Decline in Adjusted EBITDA: Adjusted EBITDA dropped significantly from $9.9 million in Q4 2023 to $584,000 in Q4 2024, indicating reduced operational efficiency.
Device Revenue Decline: Device revenue decreased from $16.3 million in Q4 2023 to $14.8 million in Q4 2024, reflecting a negative trend in product sales.
Rising G&A Expenses: G&A expenses increased to $17.3 million in Q4 2024 from $13 million in Q4 2023, suggesting rising operational costs.
Guidance Uncertainty: The company is not providing full 2025 annual guidance due to uncertainty surrounding Tricare payments, indicating a lack of visibility in future performance.
ZYXI FAQs
How does ZYXI typically perform around its earnings report dates?
ZYXI's stock performance around earnings reports can vary, but historical data shows specific patterns, such as a +0.26% change leading up to the report and a -5.29% change in the 10 days following the release.
Is Zynex Inc (ZYXI) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ZYXI Earning Call Sentiment
Zynex, Inc. (NASDAQ:ZYXI) Q4 2024 Earnings Call Transcript
ZYXI.O
-1.36%
